Inovio Pharmaceuticals, Inc. (INO) Stock Rating Upgraded by BidaskClub
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.
Several other research firms have also weighed in on INO. Stifel Nicolaus restated a “buy” rating and set a $11.00 price target on shares of Inovio Pharmaceuticals in a report on Thursday, May 25th. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a report on Tuesday, July 11th. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Inovio Pharmaceuticals in a report on Friday, June 9th. Maxim Group set a $12.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, June 8th. Finally, ValuEngine upgraded Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $19.80.
Inovio Pharmaceuticals (NASDAQ INO) traded down 0.49% on Friday, hitting $6.05. 929,728 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $5.69 and a 200-day moving average price of $6.70. Inovio Pharmaceuticals has a 12 month low of $5.28 and a 12 month high of $9.86. The stock’s market cap is $545.87 million.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The company’s quarterly revenue was up 229.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.26) EPS. Equities analysts predict that Inovio Pharmaceuticals will post ($0.92) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/09/inovio-pharmaceuticals-inc-ino-stock-rating-upgraded-by-bidaskclub.html.
A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Inovio Pharmaceuticals by 4.2% in the second quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock worth $25,301,000 after purchasing an additional 129,164 shares during the period. Wasatch Advisors Inc. increased its stake in Inovio Pharmaceuticals by 43.6% in the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after purchasing an additional 793,306 shares during the period. Northern Trust Corp increased its stake in Inovio Pharmaceuticals by 2.8% in the second quarter. Northern Trust Corp now owns 896,472 shares of the biopharmaceutical company’s stock worth $7,028,000 after purchasing an additional 24,366 shares during the period. Geode Capital Management LLC increased its stake in Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock worth $3,708,000 after purchasing an additional 62,045 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Inovio Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock worth $2,266,000 after purchasing an additional 11,765 shares during the period. Institutional investors and hedge funds own 24.83% of the company’s stock.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.